Co-Telsan (telmisartan + hydrochlorothiazide): Uses, Dosage & Side Effects

What it's for (Indications)

Telmisartan + hydrochlorothiazide is indicated for the treatment of essential hypertension in adults.
This fixed-dose combination is particularly suitable for patients whose blood pressure is not adequately controlled with telmisartan or hydrochlorothiazide monotherapy, or for whom combination therapy is considered appropriate as initial therapy if the potential benefits outweigh the risks of starting with a combination.
It is designed to provide a more comprehensive and effective blood pressure reduction compared to either agent alone, by targeting multiple physiological pathways involved in blood pressure regulation.
The use of this combination helps to achieve target blood pressure goals, which is crucial in reducing the risk of cardiovascular events such as stroke, myocardial infarction, and heart failure, as well as renal complications associated with uncontrolled hypertension.
The specific formulation of Telsarta D provides a convenient once-daily dosing regimen to improve patient adherence and sustained blood pressure control.

Dosage Information

Type	Guideline
Standard	The dosage of telmisartan + hydrochlorothiazide should be individualized based on the patient's prior response to monotherapy with either telmisartan or hydrochlorothiazide, and their specific blood pressure targets. The usual starting dose for patients whose blood pressure is not adequately controlled with telmisartan monotherapy is typically 40 mg telmisartan combined with 12.5 mg hydrochlorothiazide, administered orally once daily. If further blood pressure reduction is needed, the dose may be titrated after approximately 2 to 4 weeks of therapy, up to a maximum of 80 mg telmisartan and 25 mg hydrochlorothiazide once daily. It is essential to ensure that patients are adequately hydrated and electrolyte levels are stable prior to initiating this combination therapy, especially considering the diuretic component. Dosage adjustments may be necessary in patients with renal impairment, and the combination is generally not recommended for patients with severe renal dysfunction (creatinine clearance < 30 mL/min). The tablet should be swallowed whole with water, with or without food, at approximately the same time each day to maintain consistent drug levels and efficacy.

Type

Guideline

Standard

The dosage of telmisartan + hydrochlorothiazide should be individualized based on the patient's prior response to monotherapy with either telmisartan or hydrochlorothiazide, and their specific blood pressure targets. The usual starting dose for patients whose blood pressure is not adequately controlled with telmisartan monotherapy is typically 40 mg telmisartan combined with 12.5 mg hydrochlorothiazide, administered orally once daily. If further blood pressure reduction is needed, the dose may be titrated after approximately 2 to 4 weeks of therapy, up to a maximum of 80 mg telmisartan and 25 mg hydrochlorothiazide once daily. It is essential to ensure that patients are adequately hydrated and electrolyte levels are stable prior to initiating this combination therapy, especially considering the diuretic component. Dosage adjustments may be necessary in patients with renal impairment, and the combination is generally not recommended for patients with severe renal dysfunction (creatinine clearance < 30 mL/min). The tablet should be swallowed whole with water, with or without food, at approximately the same time each day to maintain consistent drug levels and efficacy.

Safety & Warnings

Common Side Effects

The combination of telmisartan and hydrochlorothiazide can lead to a range of side effects, primarily due to the individual components.
Common side effects associated with telmisartan include dizziness, fatigue, influenza-like symptoms, and less frequently, angioedema.
Hydrochlorothiazide frequently causes electrolyte imbalances such as hypokalemia (low potassium), hyponatremia (low sodium), and hypomagnesemia (low magnesium), which can manifest as muscle cramps, weakness, or arrhythmias.
It can also lead to hyperuricemia (elevated uric acid), potentially exacerbating or precipitating gout attacks, and hyperglycemia (elevated blood glucose), particularly in predisposed individuals.
Other common side effects from the diuretic component include orthostatic hypotension (dizziness upon standing), headache, nausea, and photosensitivity.
Less common but serious adverse effects include acute kidney injury (especially in volume-depleted patients), pancreatitis, blood dyscrasias, and idiosyncratic reactions such as acute transient myopia and acute angle-closure glaucoma due to hydrochlorothiazide.
Patients should be monitored for these effects, particularly electrolyte levels, renal function, and blood glucose levels.

Serious Warnings

Black Box Warning: WARNING: FETAL TOXICITY. When pregnancy is detected, discontinue telmisartan and hydrochlorothiazide as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Telmisartan + hydrochlorothiazide carries several important warnings.
It is contraindicated in pregnancy due to the risk of fetal injury or death, particularly during the second and third trimesters, necessitating immediate discontinuation upon detection of pregnancy.
Concomitant use with aliskiren in patients with diabetes or moderate to severe renal impairment (e.
g.
, GFR < 60 mL/min/1.
73 m²) is also contraindicated due to an increased risk of hypotension, hyperkalemia, and renal impairment.
Patients with anuria or hypersensitivity to sulfonamide-derived drugs (due to hydrochlorothiazide) should not use this medication.
Special caution is advised in patients with severe congestive heart failure, severe renal artery stenosis, or conditions leading to volume depletion (e.
g.
, severe vomiting, diarrhea, high-dose diuretics), as these can increase the risk of symptomatic hypotension and acute renal failure.
Hydrochlorothiazide can exacerbate or unmask systemic lupus erythematosus, and can also lead to acute transient myopia and acute angle-closure glaucoma, requiring immediate medical attention.
Regular monitoring of serum electrolytes (especially potassium), renal function, and blood glucose levels is crucial throughout therapy to manage potential adverse effects.

How it Works (Mechanism of Action)

Telmisartan + hydrochlorothiazide combines two antihypertensive agents with complementary mechanisms of action to achieve enhanced blood pressure reduction. Telmisartan is an angiotensin II receptor blocker (ARB), specifically and selectively binding to the angiotensin II type 1 (AT1) receptor. By doing so, it prevents angiotensin II, a potent endogenous vasoconstrictor and stimulator of aldosterone secretion, from binding to its receptor in various tissues, including vascular smooth muscle and the adrenal cortex. This blockade leads to several physiological effects: vasodilation of arterial and venous beds, reduced aldosterone secretion (which decreases sodium and water reabsorption in the kidneys), and inhibition of sympathetic nervous system activity. The net result is a significant reduction in systemic vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that acts primarily in the cortical diluting segment of the distal convoluted tubule. It exerts its diuretic effect by inhibiting the sodium-chloride cotransporter (NCC), thereby reducing the reabsorption of sodium and chloride ions from the tubular lumen. This increased excretion of sodium and chloride, along with an accompanying increase in water excretion, leads to a reduction in plasma volume, cardiac output, and ultimately, blood pressure. Additionally, long-term use of thiazide diuretics may contribute to a decrease in peripheral vascular resistance through direct vasodilatory effects. The combination offers a synergistic effect: telmisartan's blockade of the renin-angiotensin-aldosterone system (RAAS) effectively counteracts the RAAS activation that may be induced by hydrochlorothiazide, further enhancing blood pressure reduction and mitigating potential side effects like hypokalemia by reducing aldosterone-mediated potassium excretion in the renal tubules.